|
Our newest members
| Name |
Country |
Date |
| Kalevi Kairemo |
Finland |
09/09/10 |
| Lai Mun Wang |
United Kingdom |
30/08/10 |
| Lisette Saveur |
Netherlands |
25/08/10 |
| Barbara Formisano |
Italy |
23/08/10 |
| Roberto Buzzoni |
Italy |
23/08/10 |
| Daniel Kaemmerer |
Germany |
27/07/10 |
| Sobhan Vinjamuri |
United Kingdom |
23/06/10 |
| Isabel Claro |
Portugal |
14/06/10 |
Annual membership fee is EUR 30,-
To pay membership dues, registration fees or to make other payments to ENETS, please click here. We accept the following credit cards:
|
ENETS organizes an educational conference every year, to which all current and prospective members are invited. Over the past few years, the popularity of the conferences has increased substantially. The association also is involved in and supports conferences for patients with neuroendocrine tumor (NET) disease.
The 7th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease was held 11-12 March 2010 in Berlin, Germany. The conference drew a record 1,300 participants and featured nearly 150 submitted abstracts. To view the conference program, please click here. This international conference was endorsed by the European Accreditation Council for Continuing Medical Education with 12 points.
 The 6th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease was held 5-7 March 2009 in Granada, Spain. This international conference was endorsed by the European Accreditation Council for Continuing Medical Education and attracted 1,100 delegates and 120 abstracts, which have been published in Neuroendocrinology. Please click here to view the conference program. For an overview of the conference, please click here.
The 5th Annual ENETS Conference was held 6-8 March 2008 in Paris. The conference attracted 902 participants from around 55 countries.
Lectures on evaluating the updated ENETS Guidelines and TNM classification system kicked off the conference.
They were followed by sessions on animal models in NET disease; hereditary endocrine tumors; thoracic NET; test systems for new therapies for NETs and clinical implications; and novel therapies.
Two abstract sessions, one for clinical research and one for basic science, were also part of the conference. The Paris conference saw a record number of abstracts received, as well: 130.
The 4th Annual ENETS Conference was held 15-17 March 2007 in Barcelona. The conference drew around 800 participants from 50 countries, and included sessions on the ENETS Consensus Guidelines; new developments in rare hereditary diseases associated with endocrine tumors and in the imaging of NET; NET networks in Asia and South America; surgery of NETs and new therapies and clinical trials.
Over 90 abstracts, in the categories of basic science and clinical research, were submitted for review.
The 3rd Annual ENETS Conference, which was held in Prague, Czech Republic, 22-24 March attracted 706 scientists from nearly 40 countries.
The conference included lectures on the topics tumor profiling, angiogenesis, receptors and signaling, immunology and vaccination, molecular imaging, current clinical trials and new pharmaceutical developments. Abstract and poster presentations were also part of the conference, as was the annual recognition of a scientist who has achieved prominence in the field of neuroendocrine tumor research.
This year's award went to Dame Julia Polak of London.
The 2nd Annual ENETS Educational Conference was held in Cracow, Poland, 20-22 April 2005.
This conference included lectures on the diagnosis and treatment of neuroendocrine tumors and was attended by nearly 500 researchers and practicing physicians representing 40 countries. The conference was made possible through a generous educational grant from Novartis AG.
In March 2004, the 1st Annual ENETS Educational Conference, which was made possible through a generous educational grant from Novartis, was held in Budapest, Hungary.
The conference, titled "Current Status of the Diagnosis and Treatment of Hereditary and Sporadic Neuroendocrine Tumors of the Gastroenteropancreatic System," attracted nearly 350 participants from more than a dozen European countries, Russia and the U.S.
|